Emily Carter analyzes regulatory, policy, and governance issues influencing biotechnology and medical innovation. Her work examines how regulatory decisions, legal frameworks, and public policy shape research, commercialization, and patient access. At The Catalyst Brief, Emily brings a systems-level perspective, linking policy developments with scientific and market realities.
144 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryPhysician burnout is reaching critical proportions, with broad implications for healthcare outcomes, institutional performance, and patient safety. A growing body of opinion now argues for dedicated measurement and intervention programs tailored to the unique stressors of different medical specialties.
Emily CarterJul 18, 2026
Regulatory & PolicyMedicare is considering a notable policy shift that could incentivize clinicians to integrate more intensive counseling for smoking and alcohol cessation into routine patient care. With a 19% increase in reimbursement for those offering counseling, the change has the potential to address persistent challenges in preventing tobacco and alcohol-related illnesses.
Emily CarterJul 17, 2026
Regulatory & PolicyThe sudden passing of a public figure due to an aortic dissection has refocused national attention on this elusive and devastating medical emergency. Often developing over years without symptoms, aortic dissection poses complex challenges for clinicians and policymakers seeking to mitigate risk and prevent mortality. This deep-dive explores what we know, where we fall short, and what solutions may lie ahead.
Emily CarterJul 16, 2026
Biopharmaceutical IndustryA glaucoma drug acquired by Bausch + Lomb failed to meet primary and secondary outcomes in a Phase 2 study, yet the company remains optimistic about its future use in treating geographic atrophy. By pivoting focus to this significant unmet need, Bausch + Lomb aims to innovate in the eye disease space, following setbacks experienced by previous industry leaders.
Emily CarterJul 11, 2026
Biotech InnovationA new funding push by ARPA-H funnels $160 million toward custom gene editing for rare diseases, involving seven research labs and potentially catalyzing breakthroughs across the biotech sector. While the project faced delays due to administrative transitions, this large-scale investment signals robust government backing for next-generation therapeutic technologies and could reshape the landscape for treating ultra-rare conditions.
Emily CarterJul 10, 2026
Regulatory & PolicyWith the decision for a new FDA commissioner imminent, the White House is vetting a shortlist of candidates poised to shape the regulatory landscape for drugs, devices, and public health policy. This appointment comes at a pivotal time for the agency amid rapid technological, scientific, and political changes.
Emily CarterJul 8, 2026
Regulatory & PolicyAfter months of unsuccessful contract talks, nurses at Brigham and Women’s Hospital have launched a strike with wide-reaching implications—for patient care, hospital operations, and labor policy in U.S. healthcare. The dispute marks a significant moment for labor activism in medicine and spotlights broader workforce challenges.
Emily CarterJul 8, 2026
Regulatory & PolicyA new lawsuit by Elevance against HHS and CMS puts the spotlight on regulatory processes governing the crucial Medicare Advantage Star Ratings. The case underscores the growing scrutiny of how these ratings are calculated and whether all companies receive equal treatment under federal oversight.
Emily CarterJul 8, 2026
Healthcare InvestmentPrivate equity’s involvement in healthcare has long generated controversy and debate, focused traditionally on for-profit hospital and provider acquisitions. However, a new trend is drawing attention: joint ventures between private equity firms and nonprofit health systems. As this lesser-known strategy expands, questions arise about financial motivations, patient outcomes, and the degree of regulatory oversight required to safeguard the public interest.
Emily CarterJul 7, 2026
Medical TechnologyPenn Medicine has announced the rollout of K Health’s AI-driven intake solution for its virtual primary care program, representing a growing trend in healthcare’s digital transformation. This move is designed to free clinicians from time-intensive data collection tasks, potentially improving efficiency, patient experience, and allowing providers to spend more time on direct patient care. Yet, this transition prompts scrutiny around safety, accuracy, and the redefinition of patient-clinician interactions.
Emily CarterJul 7, 2026
Biopharmaceutical IndustryVertex Pharmaceuticals has announced its $10 billion acquisition of Crinetics Pharmaceuticals, a significant deal in a year shaped by a surge in biotech mergers and acquisitions. This transaction centers around Crinetics’ rare endocrine disorder assets and underscores the industry’s appetite for innovation through strategic consolidation.
Emily CarterJul 7, 2026
Biotech InnovationSince its IPO, Veradermics has experienced exceptional gains, amassing market attention by aligning its hair loss research with the runaway success of the modern obesity drug market. CEO Reid Waldman’s acknowledgment of the consumer-driven 'weight loss craze' sheds light on shifting biotech priorities and the growing synergy between metabolic and dermatological health solutions.
Emily CarterJul 6, 2026